{"type":"trials","record":{"id":29066,"source_id":"clinicaltrials-gov","external_id":"NCT06063590","title":"A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients","brief_summary":"This phase I/IIa study in frail patients is designed to assess the safety of intravenous human allogenic bone marrow-derived mesenchymal stromal cell product StromaForte by reporting the number of adverse events assessed by Common Terminology Criteria. 12 male and female patients aged 60 to 85 years will be enrolled.","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Cellcolabs Clinical SPV Limited","enrollment":12,"countries":["United Arab Emirates"],"start_date":"2024-01-22","completion_date":"2025-08-28","last_update_date":"2026-04-16","source_url":"https://clinicaltrials.gov/study/NCT06063590","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years to 85 Years","comparator":null,"organization":"Cellcolabs Clinical SPV Limited","interventions":["StromaForte"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety — 28 days post-infusion","Change in TNF-alpha — From baseline to 6 months","Change in C Reactive Protein (CRP) — From baseline to 6 months","Change in Interleukin-6 (IL-6) — From baseline to 6 months","Change in Complete Blood Count (CBC) in peripheral blood with differential — From baseline to 6 months"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Aging Frailty","StromaForte"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct06063590","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-01-22 to 2025-08-28","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.444Z","intervention":["StromaForte"],"participants":12,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety — 28 days post-infusion","Change in TNF-alpha — From baseline to 6 months","Change in C Reactive Protein (CRP) — From baseline to 6 months","Change in Interleukin-6 (IL-6) — From baseline to 6 months","Change in Complete Blood Count (CBC) in peripheral blood with differential — From baseline to 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: aging, frailty.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29066","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}